We are live on ! Find out more
NGNE icon

Neurogene
NGNE

36 hedge funds and large institutions have $38.3M invested in Neurogene in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more call options, than puts

Call options by funds: $121K | Put options by funds: $73K

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

0.11% less ownership

Funds ownership: 3.88% → 3.77% (-0.11%)

20% less funds holding

Funds holding: 45 → 36 (-9)

28% less capital invested

Capital invested by funds: $53.5M → $38.3M (-$15.2M)

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

Holders
36
Holders Change
-9
Holders Change %
-20%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
12
Reduced
11
Closed
14
Calls
$121K
Puts
$73K
Net Calls
+$48K
Net Calls Change
+$300K

Top Buyers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
+$671K
2
AFM
Anson Funds Management
Texas
+$534K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$268K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$182K
5
EP
Eversept Partners
New York
+$180K

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$1.47M
2
Citadel Advisors
Citadel Advisors
Florida
-$482K
3
MA
MYDA Advisors
New York
-$293K
4
GCP
GSA Capital Partners
United Kingdom
-$273K
5
Millennium Management
Millennium Management
New York
-$267K

NGNE Hedge Fund Activity: Q4 2018 in Review

36 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2018, worth a combined $38.3M — down 28% from $53.5M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of NGNE and 6 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 12 added.

The largest buyer was Highbridge Capital Management, adding an estimated $671K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $1.47M sold.

  • 36 institutional investors held Neurogene (NGNE) as of Q4 2018, down from 45 in Q3 2018.
  • Funds reported $38.3M of Neurogene stock for Q4 2018, down 28% quarter-over-quarter.
  • 6 funds opened new Neurogene positions in Q4 2018 and 14 closed out, a net change of -8 holders.
  • The largest Neurogene buyer in Q4 2018 was Highbridge Capital Management, an estimated $671K added.
  • The largest Neurogene seller in Q4 2018 was Ghost Tree Capital, an estimated $1.47M sold.

Based on aggregated 13F filings for Q4 2018.